TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03844295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activated Inspire® Upper Airway Stimulation System
Description: At first, INSPIRE® device will be active a month

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactivated Inspire® Upper Airway Stimulation System
Description: After 15 days wash-out INSPIRE® device will be inactivated for a second period of one month.
Study: NCT04386941

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greenlight XPS Vaporization of the Prostate
Description: The introduction of the Xcelerated Performance System (XPS) 180W in 2010 with the MoXy fibers represents the highest-powered system currently in use for this type of laser.11 It encourages the adoption of the enucleation principle, making it a real contender to HoLEP in treating large adenomas. Despite the fact that large prostates often require more energy and longer operative time, the XPS system has reduced the operative time and number of fibers required in these situations.
Study: NCT01602133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral venous puncture
Description: Ultrasound imaging of the arm is performed. If a suitable vein is identified, a percutaneous puncture is performed under ultrasound guidance. Then, an intravenous catheter is inserted according Seldinger method.
Study: NCT00593242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infusion of autologous cord blood
Description: infants who meet study enrollment criteria for history of moderate to severe hypoxic ischemic encephalopathy in the neonatal period will receive up to 4 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells. The dose for each infusion is 5x10e7 cells/kg

Intervention type: OTHER
Group type: OTHER
Intervention: Neurodevelopmental outcomes
Description: historical controls, no experimental intervention, standard therapies of hypoxic ischemic encephalopathy in the newborn period with autologous cord blood
Study: NCT02353143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN1112
Description: Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).~Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration).
Study: NCT03872947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod Cream
Description: Topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenously over 90 minutes for the first dose, over 60 for the second dose and over 30 minutes for all subsequent doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenously over 90 minutes for the first dose, over 60 for the second dose and over 30 minutes for all subsequent doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenously over 90 minutes for the first dose, over 60 for the second dose and over 30 minutes for all subsequent doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenously over 90 minutes for the first dose, over 60 for the second dose and over 30 minutes for all subsequent doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: Intravenously over 60 minutes
Study: NCT00898547

Intervention type: OTHER
Intervention: immunoenzyme technique

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT02954380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zio
Description: long term continuous monitoring
Study: NCT03872947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: Intravenously over 60 minutes
Study: NCT03789019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C1
Description: BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
Study: NCT04136444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.
Study: NCT03743961

Intervention type: OTHER
Intervention: geriatric intervention
Description: Geriatric intervention
Study: NCT00817128

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEPT
Description: Pain Exposure Physical Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CBO standard
Description: Standard therapy as defined in CBO guideline 2006
Study: NCT02132442

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ergocalciferol, placebo
Description: Ergocalciferol 50000 IU capsules Microcrystalline cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ergocalciferol, placebo
Description: Ergocalciferol 50000 IU capsules Microcrystalline cellulose
Study: NCT01940978

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate ER
Description: Watson generic, starting dose 18mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate ER
Description: Watson generic, starting dose 18mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate ER
Description: Watson generic, starting dose 18mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproheptadine
Description: cyproheptadine hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproheptadine
Description: cyproheptadine hydrochloride
Study: NCT01711385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Description: Study patients are notified of their blood test result within 72 hours. Those identified as potentially pre-diabetic or diabetic, and randomized to the enhanced intervention arm, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results or are provided with a referral to one. They are given a letter to take to their physician that specifies the risk factors identified, the tests carried out for the patient and the exact numeric results. They receive a call at month 2 to see if they have followed up with a physician regarding their test results. If they have not seen a physician regarding their results, they are advised again to do so and reminded of their individual risk factors. At month 4 they are asked again if they have seen a physician regarding their test results. If they still have not seen a physician at this time the message is reinforced. They are contacted again by phone to schedule the 6-month recall visit.
Study: NCT03290482

Intervention type: DIAGNOSTIC_TEST
Intervention: Barium Esophagram
Description: Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.

Intervention type: DEVICE
Intervention: EsophaCap
Description: Subjects will swallow the EsophaCap, which has a string attached, 10 minutes later it has devolved in the stomach. The PI will pull the string to remove the EsophaCap. We will send the sponge for cytology assessing the histologic results of eosinophils per high power field (phf)

Intervention type: DIAGNOSTIC_TEST
Intervention: Physical Examination and Questionnaires
Description: Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) at time of physical exam visit with PI.
Study: NCT04918056

Intervention type: DIAGNOSTIC_TEST
Intervention: Hematological Analysis and Genetical Analysis
Description: Hematological Analysis: Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio-Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA).~Genetical Analysis: Genomic DNA was extracted from peripheral blood (PB) by using a standard phenol/chloroform method. The genotypes of samples are analyzed by NGS assay.
Study: NCT02946931

Intervention type: DRUG
Intervention: Prizbind®
Description: Prizbind®
Study: NCT02769897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
Study: NCT01845987

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
Study: NCT01044667

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GI and Quality of Life Assessment
Study: NCT01845987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959
Description: CNTO 1959 200 mg, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
Study: NCT02108262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL112
Description: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL112
Description: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
Study: NCT02987855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipoaspiration
Description: Closed syringe harvesting subdermal fat

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ADcSVF isolation
Description: Isolation of AD-cSVF from lipoaspirate via enzymatic digestion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline IV
Description: Normal Saline IV containing autologous AD-cSVF
Study: NCT03748303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone
Description: Administration of weekly IM injections of Allopregnanolone.
Study: NCT02681263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temocillin
Description: Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.
Study: NCT02403791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linear Ultrasonic Sounder
Description: Lung ultrasound evaluation is performed after clinical assessment and before chest radiography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bedside X-ray Machine
Description: Chest Radiography is performed after clinical evaluation without using ultrasound assessment.
Study: NCT04040426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human split thickness skin allograft
Description: Application of a fenestrated human skin graft

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional Outer Dressing Applicaiton
Description: Application of Moisture retentive dressing, and a multi-layer compression dressing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Outer Dressing Applicaiton
Description: Application of Moisture retentive dressing, and a multi-layer compression dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibracol Wound Dressing
Description: Application of Collagen Alginate Dressing
Study: NCT03064334

Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: surgical knee joints Arthroplasty
Study: NCT03552081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fragmented DNA evaluation in blood and semen samples
Description: The objective will be to evaluate the decrease in the percentage of sperm with spermatic DNA fragmentation by the TUNEL technique following the evolution of this rate to 3 months, 6 months and 12 months after cessation of smoking by blood and semen samples.
Study: NCT03706586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 30% group
Description: Infants in the 30 % group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
Study: NCT01169883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Peer Support
Description: The Coping Peer Support is delivered at weekly group meetings over the 10 week active treatment phase. The Coping Peer Support consists of: group support, coping peer group problem solving, and development and recording of Coping Peer Asthma Messages. More specifically, a social worker facilitates a peer group discussion of barriers to taking their daily inhaled steroids, and ways to overcome these barriers. The social worker also facilitates peer recording of messages by the participants encouraging each other to take their daily inhaled steroid medication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Doctor Asthma Messages
Description: The attention control group will receive Doctor Asthma Messages delivered during the 10 week active treatment phase. The content and number of these messages will be equivalent to those received by the intervention group. These messages are developed and recorded by an Allergist/Immunologist. The participants in the attention control group will listen to these Doctor Asthma Messages, between their favorite music tracks on their MP3 player, as they go about their day-to-day activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Peer Asthma Messages
Description: The Coping Peer Asthma Messages developed and recorded by study participants for each other at the weekly coping peer group meetings will be placed on intervention group participants' MP3 players. These Coping Peer Asthma Messages will be played on their MP3 players, between their favorite music tracks, during the course of their daily routines. This infuses the coping peer support from the coping peer group meetings into the adolescents' daily routines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Supervision
Description: A member of the study team meets individually with each participant at baseline to teach proper use of a peak flow meter and spacer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Supervision
Description: A member of the study team meets individually with each participant at baseline to teach proper use of a peak flow meter and spacer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Tracks
Description: Participants receive an MP3 player (iPod Shuffle) in the baseline period. Participants receives clean, radio-edited music tracks of their choice in the baseline period and 10 week active treatment period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Tracks
Description: Participants receive an MP3 player (iPod Shuffle) in the baseline period. Participants receives clean, radio-edited music tracks of their choice in the baseline period and 10 week active treatment period.
Study: NCT01591603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1 cm
Description: A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 1 cm past the tip of the Tuohy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5 cm
Description: A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 5 cm past the tip of the Tuohy
Study: NCT02188303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2944876
Description: Administered SC
Study: NCT03706586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 60% group
Description: Infants in the 60 % group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
Study: NCT00120003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil
Description: 4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
Study: NCT01586845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voclosporin
Description: Initial dose of voclosporin 0.8 mg/kg BID, then concentration controlled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: tacrolimus as per labeled dose
Study: NCT04004052

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Electrical Nerve Stimulation (TENS)
Study: NCT02188303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2944876
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT00470821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral melatonin 3mg BID
Description: Identical tablets containing melatonin 3 mg. Nurses are requested to give two tablets daily, at 8 PM and 12 PM

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical tablets without the active principles. Each evening nurses are requested to give 2 tablets at 8 PM and 12 PM
Study: NCT00368706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolterodine
Description: oral
Study: NCT01106547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 125mg
Description: Single dose 60-90 minutes preoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 2 ml
Description: Single dose 60-90 min preoperatively
Study: NCT04526184

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise with blood flow restriction
Description: Patients and healthy individuals will be given 30 minutes of aerobic exercise by cycling, by restricting lower extremity blood flow.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise with blood flow restriction
Description: Patients and healthy individuals will be given 30 minutes of aerobic exercise by cycling, by restricting lower extremity blood flow.
Study: NCT03184948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brilliance
Description: The intervention is the provision of the Brilliance phototherapy machines to hospitals. This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method. In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brilliance
Description: The intervention is the provision of the Brilliance phototherapy machines to hospitals. This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method. In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.
Study: NCT02243501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
Study: NCT00323661

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate-adaptive pacemaker: accelerometer
Description: Accelerometer based pacing rate adaptation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rate-adaptive pacemaker: Closed Loop Stimulation
Description: Closed Loop Stimulation (CLS) is a unique concept in rate-adaptive pacing that uses the natural cardiovascular control loop to determine the appropriate pacing rate. Closed Loop Stimulation is the only rate-adaptive system responding to mental stress and thereby assuring optimal cerebral perfusion in everyday activity.
Study: NCT01798303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940094
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT02188303

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC